Intelligent Market Insights

Posting Market Insights that are the outcome of the detailed analysis of markets by Market Experts

Burn Care Market Necessity and Demand 2019 to 2026

Burn wounds are extremely painful, highly traumatic, and can lead to permanent scarring, disfigurement or even death. The management of these wounds is based on the injured area and severity and depth of burn. Burn care market has witnessed various technological advancements to treat all degrees of burns injuries. For instance, in July 2016, a combined team of researchers from the Boston University and Beth Israel Deaconess Medical Center developed new type of hydrogel bandage for burn patients. The hydrogel bandage seals the burn wounds to prevent entry of bacteria and proven to be easily removable.


Ask For a Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1279


Market Dynamics


Increasing fire incidences are expected to lead to high demand for treatment of burn injuries, which is expected to drive growth of the burn care market. For instance, in January 2017 , according to the World Health Organization (WHO) data published in the African Journal of Emergency Medicines, burn injuries lead to around 18 million disability cases and over 2,50,000 deaths, annually, of over 90% deaths are registered from low-and middle-income countries. Moreover, the U.S. Fire Department responded to around 1.3 million fire incidences in 2016 and the National Fire Protection Association (NFPA) reported 3,280 civilian deaths and 15,700 civilian injuries in these incidences.


However, increasing number of product recalls due to product failure, component inconsistency, and packaging problems is expected to hamper growth of the burn care market. For instance, in March 2018, Integra LifeSciences Corp. recalled its Manuka Honey Wound Gel, which is used for wound healing of minor scalds and burns, minor cuts, lacerations, and minor abrasions. The reason for recall was incorrect gel part number listed in a master manufacturing record. The product was finally terminated in July 2018.


Global Burn Care Market- Drivers


The burn care market is expected to witness significant growth in the forecast period, owing to increasing incidence of burn injuries. For instance, according to the World Health Organization (WHO) data of March 2018, it is estimated that 180,000 deaths are caused by burns, annually, worldwide. Moreover, a vast majority of these deaths occur in low- and middle-income countries.


Increasing awareness regarding burn care is also expected to drive the burn care market growth over the forecast period. For instance, in February 2019, the American Burn Association organized National Burn Awareness Week in the first full week of the month, which served as an opportunity for burn care organizations, burn survivor support groups, public safety professionals, and injury prevention activists to increase awareness among the population about the frequency and causes of burn injuries in the U.S.


Purchase This Premium Report @ https://www.coherentmarketinsights.com/insight/buy-now/1279


Global Burn Care Market- Competitive Landscape


Key players operating in the global burn care market include, Smith & Nephew Plc. Molnlycke, ConvaTec Inc., Integra LifeSciences Corporation, 3M, Coloplast A/S, Cardinal Health, Inc., DeRoyal Industries, Inc., Acelity LP, and Svenska Cellulosa Aktiebolaget (SCA).


Detailed Segmentation:

  • Global Burn Care Market, By Product Type:
    • Advanced Burn Care
    • Biologics
    • Traditional Burn Care
  • Global Burn Care Market, By Burn Degree:
    • First-Degree
    • Second-Degree
    • Third-Degree
    • Other Degrees


Global Burn Care Market- Regional Insights


On the basis of region, the global burn care market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold dominant position in the global burn care market during the forecast period, owing to presence of major market players in the U.S. such as Acelity LP, 3M, Coloplast A/S, and Integra LifeSciences Corporation.


Asia Pacific is expected to witness a rapid growth in the global burn care market, during the forecast period, owing to increasing government initiatives for burn treatment. For instance, in 2016, Government of India, introduced National Program for Prevention, Management, and Rehabilitation of Burn Injuries (NPPMRBI) in India. This program is implemented through state government medical colleges and district hospitals with the objective to reduce the incidence, morbidity, mortality, and disability due to burn injuries.


About Coherent Market Insights:


Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.


Contact Us:


Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: sales@coherentmarketinsights.com

Veterinary Chemistry Analyzers Market: Future and Technological Advancement 2026

A veterinary chemistry analyzer (VCA) is used for in-house veterinary use. These analyzers are used to determine the concentration of certain metabolites, proteins, electrolytes or drugs in samples of urine, plasma, serum, cerebrospinal fluid and/or other body fluids of animals. In other words, VCA is a blood and urine testing instrument that analyzes around 12 biochemical tests simultaneously, by using the samples of either urine, serum or plasma in around 6 minutes. The types of analyzers include, urine analyzers, blood gas & electrolyte analyzers, glucometers, and others, which are used by hospitals, medical labs, and for home use. There are several types of tests such as hematology test that includes the cell counter for blood counts, immunoassays for detecting antibodies, and tests for ions that measure voltage differences and others.


Ask For a Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/2677


Veterinary Chemistry Analyzers Market - Drivers


Increasing animal population, growing pet adoption, increasing demand for pet insurance, along with high animal health expenditure and increase in number of veterinary practitioners are the factors driving growth of the veterinary chemistry analyzers market. According to the data published by American Pet Product Association (APPA) in 2018, total pet healthcare expenditure in America in 2017 was US$ 69.51 billion, which reached to US$ 72.13 billion in 2018.


Increasing prevalence of zoonotic diseases is further contributing towards growth of the veterinary chemistry analyzers market. According to the Centers for Disease Control and Prevention (CDC) in 2017, 3 out of 4 emerging infectious diseases in people are transmitted through animals. E.coli infection, chickungunya, dengue, and malaria are some mild to severe zoonotic diseases. According to the World Health Organization, in 2015, around 212 million cases of malaria were recorded worldwide with 429,000 deaths. Therefore, increasing need for control measures for zoonotic diseases is expected to boost the market growth. 


Key manufacturers in the market are focused on launching new veterinary chemistry analyzers, which is expected to boost the market growth. For instance, in November 2015, Diatron Group, global provider of hematology and clinical chemistry analyzers, launched a new 5-part differential veterinary hematology analyzer- the Abacus Vet5 in Dusseldorf at the Medica show.


Veterinary Chemistry Analyzers Market - Competitive Landscape


Some of the key players operating in the global veterinary chemistry analyzers market include, Abaxis Inc., IDEXX Laboratories Inc., Heska Corporation, DiaSys Diagnostics Systems, Derechos reservados Diconex, URIT Medical, Randox Laboratories Ltd., Eurolyser Diagnostica GmbH, ARKRAY Inc., and Alfa Wassermann Inc.


Purchase This Premium Report @ https://www.coherentmarketinsights.com/insight/buy-now/2677


Veterinary Chemistry Analyzers Market - Market Taxonomy


On the basis of modality, the global veterinary chemistry analyzers market is segmented into:

  • Benchtop
  • Portable

On the basis of product type, the global veterinary chemistry analyzers market is segmented into:

  • Instruments
  • Consumables

On the basis of animal type, the global veterinary chemistry analyzers market is segmented into:

  • Companion Animals
  • Livestock

On the basis of application, the global veterinary chemistry analyzers market is segmented into:

  • Blood Chemistry Analysis
  • Glucose Monitoring
  • Blood Gas & Electrolyte Analysis
  • Urinalysis

On the basis of end user, the global veterinary chemistry analyzers market is segmented into:

  • Hospitals
  • Clinical Laboratories


Veterinary Chemistry Analyzers Market - Regional Insights


On the basis of region, the global veterinary chemistry analyzers market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds dominant position in the global veterinary chemistry analyzers market. This is owing to increasing animal health expenditure and high demand for animal-derived food in the region. According to American Pet Products Association, the total pet industry expenditure which includes the food, supplies and over the counter medicine, in 2017 was US$ 69.4 billion.


Key market players in the region are focused on adopting acquisition strategies to expand their geographical presence. For instance, in May 2018, Zoetis Inc. and Abaxis Inc. announced the definite merger agreement in which Zoetis Inc. will acquire Abaxis Inc. This acquisition is expected to improve Zoetis Inc.’s presence in the veterinary diagnostics sector.


About Coherent Market Insights:


Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.


Contact Us:


Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: sales@coherentmarketinsights.com

Outsourced Drug Discovery Market Set for Rapid Growth and Trend, by 2026

Outsourced drug discovery is a contract-based process, which is conducted by the contract research organizations (CRO) and contract manufacturing organizations (CMO). Contract research organization provides support to the pharmaceutical, biotechnology, and medical device industries for drug discovery and development. CRO facilitates various services such as biopharmaceutical development, biologic assay development, preclinical research, clinical trials, and pharmacovigilance, for drug discovery and development.


Ask For a Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/2847


Market Dynamics


New strategies adopted by key players related to outsourcing drug discovery is expected to drive the growth of the global outsourced drug discovery market. For instance, in June 2019, GlaxoSmithKline (GSK), a British drug manufacturing company collaborated with the University of California to establish a state-of-the-art laboratory for CRISPR technologies, the Laboratory for Genomics Research (LGR), in San Francisco. The new laboratory will investigate how gene mutations cause diseases, and also develop new technologies using CRISPR to rapidly accelerate the discovery of new medicines.


Furthermore, the extension of partnership activities is expected to propel global outsourced drug discovery market growth. For instance, in March 2017, Charles River Laboratories (CRL) extended its partnership with Chiesi Farmaceutici. Under this partnership, Charles River Laboratories (CRL) extended its longstanding, strategic, integrated drug discovery program (Respiratory Program). The respiratory program is related to preclinical drug development for the treatment of respiratory diseases and rare diseases.


The increasing number of drug discovery companies is expected to drive the growth of the global outsourced drug discovery market


The increasing number of new drug discovery companies is expected to drive the global outsourced drug discovery market growth. For instance, in November 2018, Schrodinger, LLC collaborated with Wuxi AppTec and launched a new drug discovery company, Faxian Therapeutics (Headquarter– New York, U.S.). Faxian Therapeutics will utilize the Schrodinger, LLC’s computational platform and WuXi’s drug design and synthesis services to improve health care needs.


Moreover, rising drug discovery services are expected to propel the growth of the global outsourced drug discovery market. For instance, in April 2019, Eurofins Discovery Services, a contract research organization, launched a new drug discovery service DiscoveryOne. The new approach is helpful for drug discovery research activities and preclinical developments. Hence, the launching of services related to drug discovery is expected to support the global outsourced drug discovery market growth.


Global Outsourced Drug Discovery Market - Competitive Landscape


Key players operating in the global outsourced drug discovery market are Aurigene Accelerating Discovery, Bioduro LLC, Charles River Laboratories (CRL), Chempartner, TCG Lifesciences, Evotec AG, Syngene International Ltd., Jubilant Biosys Ltd, Pharmaron Inc., Shanghai Medicilon, and Sundia Meditech Co. Ltd.


Detailed Segmentation:

  • Global Outsourced Drug Discovery  Market, By Drug Type:
    • Small Molecule Drugs
    • Large Molecule Drugs
  • Global Outsourced Drug Discovery Market, By Services:
    • Preclinical Development
    • Target Validation and Functional Informatics
    • Target Identification and Screening
    • Lead Identification and Candidate Optimization
    • Others
  • Global Outsourced Drug Discovery Market, By Application
    • Oncology
    • Ophthalmology
    • Hematology
    • Immunomodulation
    • Anti-Infective Drugs
    • Dermatology
    • Pulmonology
    • Cardiology
    • Others
  • Global Outsourced Drug Discovery Market, By End User
    • Pharmaceutical and Biotechnological Companies
    • Contract Research Organization
    • Contract Manufacturing Organization


Global Outsourced Drug Discovery Market- Regional Analysis


North America outsourced drug discovery market is expected to account for the largest market share, owing to business expansion in this region. For instance, in January 2019, Lambda Therapeutic Research (Headquarter-India) acquired Novum Pharmaceutical Research Services, a U.S. CRO. With this acquisition, Lambda Therapeutic Research entered into the U.S. market.


Purchase This Premium Report @ https://www.coherentmarketinsights.com/insight/buy-now/2847


Moreover, Europe is also projected to witness significant growth in the global outsourced drug discovery market, owing to increased merger and acquisition activities by key players in the region. For instance, in February 2019, Optimapharm, a clinical research organization (CRO) in Europe acquired Denothex, a CRO, for strengthening its presence in the European market particularly in France, Spain, Switzerland, and Italy. Denothex conducts all clinical trials in oncology across Europe and Israel.


About Coherent Market Insights:


Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.


Contact Us:


Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: sales@coherentmarketinsights.com

Cannabis Testing Services Market: Effect and Growth Factors Research and Projection 2018-2026

Cannabis market is highly influenced by rigorous legalization efforts, which are aiming for approval of cannabis for medicinal or recreational purpose. Various governments and regulatory authorities are taking efforts to legalize cannabis, owing to its medicinal benefits. Moreover, commercialization of cannabis-based products under the legalized standards require successful cannabis testing, which further results in lucrative growth opportunity for market players.


Ask For a Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/2976


Market Dynamics


Cannabis testing service market is expected to witness significant growth over the forecast period, owing to legalization of cannabis for medicinal and recreational activities in key regions. For instance, in 2018, the parliament of Canada passed a law legalizing nationwide use of marijuana for recreational purposes. Furthermore, in February 2016, the Australia government amended the Narcotics Drugs Act 1967 to allow cultivation of cannabis for medicinal or scientific purposes under a national licensing scheme, which is expected to favour growth of the commercial manufacturing of cannabis in different regions of Australia.


Increasing Research & Development Activities in Cannabis and Establishment of New Cannabis Testing Labs is expected to Drive Growth of the Cannabis Testing Service Market


Increasing research and development activities in cannabis to improve the productivity and quality of cannabis product is major driving force for the global cannabis testing service market growth. For instance, in November 2018, a team of researchers at the University of Guelph investigated technologies that can help in growing better quality marijuana. The team focused on controlled environment production of medical marijuana, with proprietary plant-growing technology, using chambers to monitor and regulate all variables throughout the growth.


Moreover, the research also involved sensors attached to the plants to analyze the plants’ response to different types of management strategies. This approach allowed the team to produce organically grown, pesticide-free, high-yielding strains of cannabis, in addition to consistent generation of high-quality products in every batch.


Global Cannabis Testing Service Market - Competitive Landscape


Key players operating in the global cannabis testing service market include, SC Laboratory, Eurofins Scientific, EVIO Labs, ProVerde Laboratories, Inc., Praxis laboratory Cascadia Labs, Encore labs, SGS Canada Inc., Pharm Labs LLC, and Agricore Laboratories.


Purchase This Premium Report @ https://www.coherentmarketinsights.com/insight/buy-now/2976


Detailed Segmentation:

  • Global Cannabis Testing Services Market, By Test Type:
    • Potency Testing
    • Terpene Profiling
    • Cannabinoid Profiling
    • Pesticide Screening
    • Residual Solvent Testing
    • Microbiological Screening
    • Other Tests
  • Global Cannabis Testing Services Market, By End User:
    • Cannabis Firms
    • Homecare Settings
    • Research Institutes


Global Cannabis Testing Service Market - Regional Insights


On the basis of region, the global cannabis testing service market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global cannabis testing service market during the forecast period, owing to increasing legalization of marijuana use in the U.S. by Federal Law. For instance, according to the Drug Policy 2018 report, on November 6, 2012, Colorado and Washington become the first two jurisdictions in the world to legalize marijuana for adult use. Moreover, in January 2018, Vermont became the first state to legalize marijuana through a state legislature. According to Governing 2019 report, 11 states have legalized marijuana for recreational use and 22 states have legalized for medical use in the U.S.


Europe is expected to foresee a rapid growth in the cannabis testing service market. The market in Europe is expected to gain momentum during the forecast period, owing to increasing number of players entering the U.K. cannabis testing service market by acquiring U.K-based cannabis testing laboratories. For instance, in July 2018, Sativa Investments PLC acquired PhytoVista Laboratories Ltd., a U.K-based lab that tests cannabis oils and hemp products.


About Coherent Market Insights:


Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.


Contact Us:


Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: sales@coherentmarketinsights.com

Bioactive Peptide Market to Grow at a High CAGR of by 2026

The bioactive peptides are ingredients that provide nutritive value to the food by adding protein and other important nutrients. Bioactive peptides are gaining popularity owing to health benefits such as prevention and control of chronic disease conditions like cardiovascular disease, diabetes, cancer, and infectious diseases. Therefore, bioactive peptides used as treatment therapy for most of the functional disorders such as irritable bowel disease is expected to enhance the market growth.


Market Dynamics


Technological innovations and developments in extraction techniques of bioactive peptide from natural sources is contributing to the market growth. For instance, an article was published in the journal of 'Critical reviews in environmental science and technology' in June 2019, regarding recent developments in native bioactive peptides targeting informatics, novel microbial protease mining, and screening methods, which are expected to accelerate development of genome-based microbial routes to therapeutic bioactive peptides, that promote human health and nutrition. As a result, technological advancements and genetically modified products is expected to propel the growth of the bioactive peptide market.


Increasing incidence of chronic diseases such as diabetes, cancer, cardiovascular disease, chronic obstructive pulmonary disease (COPD), and others is propelling the global bioactive peptide market growth.


Increasing incidence of diseases like diabetes, cancer, and respiratory disorders is expected to drive growth of the global bioactive peptide market. According to the International Federation of Diabetes, 2017 report, around 425 million adults were suffering from diabetes globally, and the number is expected to reach 629 million by 2045.


According to a press release on September 2018 by the International Agency for Research on Cancer, the global cancer burden is estimated to have risen to 18.1 million new cases and 9.6 million deaths in 2018. Moreover, 1 in 5 men, and 1 in 6 women worldwide develop cancer during their lifetime, and 1 in 8 men, and 1 in 11 women die from the disease.


Growing Demand for nutritional supplements


There has been increasing awareness among the populace regarding disease conditions, owing to initiatives and campaigns by government organizations, and increasing healthcare spending by government organizations are projected to drive growth of the global bioactive peptide market. According to Council for Responsible Nutrition (CRN) Washington, October 2018, Consumer Survey on Dietary Supplements, conducted by Ipsos Public Affairs found that 75% of U.S. adults take dietary supplements in 2018, compared to 65% in 2009.


Key Players


Major players operating in the global bioactive peptides market include Archer Daniels Midland Company, Seagarden AS, Phermpep Co. Ltd., Arlak Biotech Pvt. Ltd., Naturade, Royal DSM, MYOS RENS Technology Inc., Natural Factors Inc., and Valio Oy among others.

  • Global Bioactive Peptide Market, By Source:
    • Plant
    • Milk
    • Eggs
    • Meat
    • Fish
  • Global Bioactive Peptide Market, By Therapeutic Area:
    • Antihypertensive
    • Antioxidant
    • Immunostimulatory
    • Antimicrobial
    • Diabetes
    • Others
  • Global Bioactive Peptide Market, By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy

Bioactive peptides are amino acids combined together through a covalent bond. Bioactive peptides are extracted from various natural sources, thereby providing a variety of health benefits such as better cardiovascular, digestive, endocrine functioning, as well as the immune and nervous system. They are also used in protecting important contents of food and beverages, resulting in decreased oxidation and degradation of the products. Although these peptides are extracted from natural sources, some of them have been designed with the help of chemical synthesis.


Furthermore, bioactive peptides, as well as bioactive proteins are part of a balanced diet. The prominent factor driving the market demand is increasing incidence of chronic diseases, and growing geriatric population. Moreover, growing interest in bioactive peptides is driving the scientific community and the food industry to develop new food additives and functional products based on bioactive peptides.


About Coherent Market Insights:


Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.


Contact Us:


Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: sales@coherentmarketinsights.com

Gel Permeation Chromatography (GPC) Market To Be At Forefront By 2025

Gel permeation chromatography is a size exclusion based chromatography technique. It is most commonly used to determine the molecular weight distribution of the polymer which confirms its purity. It is also used to separate various component of the analyte, based on their retention with stationary phase. Both aqueous and non-aqueous mobile phases are used in gel permeation chromatography based on analyte and column’s packing material. Variety of detectors can be used such as refractive index detectors, light scattering detectors, viscometer, and diode array/UV detectors, which measures concentration, informs about size, and structure of analyte.


Request For a Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/28


Market Dynamics


Major factor driving growth of the gel permeation chromatography market is increasing research for chronic disease such as cancer. According to report by International Agency for Research on Cancer (IARC) in 2012, around 14.1 million new cases, 8.8 million deaths, and 32.6 million people were suffering from cancer worldwide. North America has high incidence of cancer with an estimated 1,735,350 new cancer cases to be diagnosed in the U.S. in 2018, as reported by American Cancer Society’s Cancer Journal for Clinicians. Companies are focusing on protein-based gene therapy also termed as personalized medicine that studies various body proteins such as monoclonal antibodies for developing novel therapies. GPC system is used in this process to know molecular weight, separation as it would decide final physical attribute of the analyte. Expiration of patent of blockbuster drugs such as Rituximab is leading to development of biosimilar versions of the same drugs, where GPC system is important to compare and profile biosimilar and innovator molecule. Major players are also bringing products with new technologies and multiple detectors to precisely analyze the polymers.


Increasing research and development by pharmaceutical and biotech companies in chronic disease is expected to propel growth of the gel permeation chromatography market


Increasing focus on research and development activities by pharmaceutical and biotech companies across the globe, targeting chronic diseases such as cancer to bring novel therapies, is expected to aid in growth of the market. These are protein (Natural Polymer) based therapies such as CAR-T cell therapy, antibody-drug conjugates, and immune check point inhibitors. According to report in 2017 by International Federation of Pharmaceutical Manufacturers and Associations, research based pharmaceutical and biotech companies annually invest around US$ 149 billion on research and development. Over 7,000 molecule are under investigation, out of which around 2,000 candidate are for cancer. Therefore, separation and characterization of new chemical entity, which are polymer-based is possible efficiently with gel permeation chromatography and this is expected to aid in growth of the market in the near future.


Key players operating in gel permeation chromatography market are Agilent Technologies, Waters Corporation, Malvern Panalytical, Shimadzu Corporation, and Polymer Char.


Detailed Segmentation:

  • Global Gel Permeation Chromatography Market, By Product Type:

    • Gel Permeation Chromatography System

    • Detectors

    • Columns

    • Pumps

  • Global Gel Permeation Chromatography Market, By End User:

    • Pharmaceutical and Biotech Companies

    • Research Institutes


Regulatory approvals for use of novel excipients (Polymers) is expected to drive growth of the gel permeation chromatography market


Pharmaceutical and biotech companies widely use polymers as excipient (Binder, Diluent, coating agents, suspending agent, viscosity agent, and Disintegrant) to produce variety of dosage form. There is increasing use of natural polymers instead of synthetic one due to inertness, low cost, and higher acceptability of consumers towards natural polymers. Various recently launched natural polymers from different manufacturers are Solutol HS 15, Soluplus, Kollicoat Smartseal 30 D, Polyplasdone Ultra, and Prosolv ODT. However, before using polymers in formulation, end user (pharmaceutical and biotech companies) has to be confident about quality of polymers used as excipients. Click to Read More On Gel Permeation Chromatography (GPC) Market.


About Coherent Market Insights:


Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.


Contact Us:


Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Hutchinson-Gilford Progeria Treatment Market Industrial Progress 2018 to 2026

Hutchinson-Gilford progeria syndrome is a genetic condition characterized by the dramatic, rapid, appearance of aging from the childhood. Hutchinson-Gilford progeria syndrome is caused by a mutation in the lamin A (LMNA) gene. The affected children develop a characteristic facial experience including prominent eyes, small chin, protruding ears, thin lips and a thin nose with a beaked tip. This syndrome also causes hair loss (alopecia), joint abnormalities, aged-looking skin, and a loss of fat under the skin (subcutaneous fat). Moreover, patients of Hutchinson-Gilford progeria syndrome experiences severe hardening of the arteries (arteriosclerosis) from the childhood. The condition worsens with age and increases the risk of heart attack or stroke even at a young age.


Request For a Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/35


Hutchinson-Gilford progeria is a rare condition that affects about one in four million newborns worldwide according to the National Institutes of Health (NIH). Until now more than 130 cases have been reported as per the NIH statistics. The affected patients live up to 30 years maximum, with an average life span of 13 years. Nearly 90% of the patients die from complications related to atherosclerosis. Till 2012 there wasn’t any effective treatment therapy discovered for Hutchinson-Gilford progeria syndrome. The treatments available focused mostly on reducing cardiovascular symptoms and growth abnormalities.


Farnesyltransferase Inhibitor (FTI)


In 2012, findings of the first clinical trial of the drug Lonafarnib, a farnesyltransferase inhibitor (FTI), gave a new hope for the treatment of children with Hutchinson-Gilford progeria syndrome. Clinical trial results demonstrated improvement in weight gain, increase in bone mineral density, reduced vascular stiffness, and improved sensorineural hearing in patients with progeria. Previous treatments with growth hormone, and Sulforaphane helped in reducing the symptoms, and prolong a child’s life. However, it is essential that the patient regularly visits the cardiologist. Rapamycin is one other drug used before, that demonstrated to reverse nuclear blebbing, retard cellular senescence, and facilitate degradation of progerin.


Recently in 2015, the scientists at the Agency for Science, Technology & Research (A*STAR) successfully established a model of Hutchinson-Gilford progeria syndrome. The study conducted by this organization proposed a model which implies that progerin is linked to telomeres. Progerin induces a reduction in heterochromatin, a tightly packed form of DNA, making telomeres in the cell more fragile and susceptible to damage. The damaged telomeres in turn trigger premature cellular aging. This model is radically different from the one believed earlier – the gene progerin caused the nucleus to be deformed, thereby weakening the ability of cells to divide and proliferate. The altered progerin protein makes the nuclear envelope unstable and progressively damages the nucleus, making cells more likely to die prematurely.


Researchers are working to determine how genetic changes further leading to the characteristic features of Hutchinson-Gilford progeria syndrome. Continuous advancement in research with increased understanding of the human aging will provide valuable insights and aid in the treatment of this disease. Click To Read More On Hutchinson-Gilford Progeria Treatment Market.


About Coherent Market Insights:


Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.


Contact Us:


Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Medical Claims Processing Services Market Widespread Research and Fundamental study to 2026

Medical Claims Processing Services


As the global healthcare industry continues to expand, healthcare providers are facing challenges in maintaining optimal quality of services. Number of claims are increasing with increasing coverage of medical insurance. Processing such claims along with the administrative tasks, patient care, and other daily operations is cumbersome and involves high cost and trained personnel. Processing of claims in-house by the healthcare provider has the risk of delayed payment, error in amounting, and customer dissatisfaction. Moreover, healthcare providers need to be updated with changes in regulations and new services and products being launched in the market for in-house processing of claims.


Request For a Sample Copy of This Business Report @ 
https://www.coherentmarketinsights.com/insight/request-sample/41


Outsourcing of medical claims ensures minimal error and faster turnover, thereby reducing risk of delayed payment. According to the American Medical Association (AMA), 20% error rate among health insurers represents an intolerable level of inefficiency that causes a loss of around US$ 17 billion each year. This depicts a strong need for adequate and technically advanced claim processing services and software to reduce the economic burden.


Earlier, claims were submitted using a paper form. However, with the advent of healthcare IT, most claims are now electronically made i.e. electronic data interchange. The onset of online medical claim process reduces paperwork of healthcare providers and also assists in rendering adequate fees for the services. Usually the medical claims are processed by medical claims examiners or medical claims adjusters. In case of large number of claims though, medical directors review the claim and validate its authenticity.


The medical claims processing services market can be analyzed for:

  • Claim indexing

  • Claim investigation

  • Claim adjudication

  • Claim repricing

  • Claim settlement

  • Litigation management and

  • Information management services


Most of these services are either directly rendered by the service provider or can be outsourced to third-party organizations for code assignment and claim processing. Outsourcing concept reduces the burden as well as cost for insurance companies. Most billing services charge a percentage of the collected claim amount. The concept of EMR/EHR has also streamlined claim processing, as patient records are electronically transmitted to the billing service providers, which eliminates the process of recording and sending paper-based records.


Medical Claims Processing Services Industry Outlook is Positive in Developed Economies


According to Swiss Re, the global insurance penetration rate was a mere 6.2% in 2014, with India having insurance penetration rate on the lower side, at just 3.9% in the same year. Moreover, the study found that the insurance penetration rate fell to 3.2% in 2015 in India. The U.S., Japan, U.K., Australia, Italy, and France are some of the leading countries in the global medical claims processing services market, owing to higher insurance penetration rate, increasing number of claims, and growing demand from healthcare providers. Furthermore, favorable healthcare policy and government initiatives such as Affordable Care Act have also boosted demand for medical claim processing services in the U.S. Europe is quickly emerging as another important Medical Claims Processing Services Market.


Although the medical claims processing services market in Asia Pacific and Rest of the World are still at a very nascent stage, high population base and increasing awareness for insurance in the middle income group is expected to boost demand for medical claim processing services in the near future.


Medical Claims Processing Services Market Competitive Landscape


Some of the prominent players in the global medical claims processing services market include Aetna Inc., Infinit Healthcare, Invensis Technologies Pvt. Ltd, Humana Inc., UnitedHealth Group, Telegenisys Inc., and Health Care Service Corp.


About Coherent Market Insights:


Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.


Contact Us:


Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Mobile Health Apps and Solutions Market: Future and Technological Advancement 2026

Mobile Health Apps and Solutions Market Overview


Proliferation of mobile devices provides an entirely new and effective dimension to the healthcare industry, wherein solutions can be provided to end users in an extremely easy-to-use manner that can be accessed irrespective of the use location. Advent of mHealth apps and solutions have led the healthcare solutions market to expand its reach from hospitals to primary care and office space. The industry is witnessing influx of various start-ups venturing into the market, leading to high competition.


Request For a Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/42


Mobile health apps segment is expected to grow at impressive double digit CAGR over the forecast period (2016–2024), creating new market opportunities for the players worldwide.


Proliferation of smartphones fueling mobile health apps and solutions market growth


Over 600 million people are expected to use mobile healthcare apps by 2017, creating a highly lucrative market opportunity for healthcare players. The industry is projected to be mainly driven by growing healthcare expenditure and consumer changing lifestyle. Advancements in computing ability of mobile devices would bridge the gap between patient’s expectation and treatment delivered. The technology is perceived to be an enabler of quality healthcare.


Though the industry is set to grow at a robust rate, lack of collaborations among healthcare service providers and low healthcare apps utilities awareness among the masses are major industry pitfalls.


Mobile Health Apps and Solutions Market Taxonomy:


Coherent Market Insights has segmented the mobile health apps and solutions market on the basis of following:

  • Operating System

  • Product Type

  • Therapeutic Application

  • Devices


On the basis of operating system, iOS mHealth app is expected dominated the market in 2015. However, the segment is expected to lose major market share to android app segment by 2024.


Among device segments, smartphones are expected to dominate the market, followed closely by tablets through 2024. Tablets are expected to be most prominent in developed regions.


Mobile Health Apps and Solutions Market – Competitive Landscape


Major players in the mobile health apps and solutions market include Runtastic, Nike, MyFitnessPal, Azumio, GP Apps, Pacer Health, Kinosis, GoodRX, Leafly, and Epocrates.


Emergence of connected and integrated healthcare solutions driving growth of North America and Europe markets


The mobile health apps and solutions market
 report covers market analysis across regions namely North America, Europe, Asia Pacific, Latin America, Middle East and Africa.


Geographically, Europe, followed closely by North America is expected to dominate the market throughout the forecast period. Presence of leading mHealth service providers, along with wide availability of high-quality healthcare amenities, and increased healthcare awareness is expected to bolster market growth.


The market in Asia Pacific is growing at the fastest rate, driven primarily by rising demand in China and India. China and India account for over 36% of global population, creating lucrative market opportunity for players in the long run. Markets in Latin America, Middle East, and Africa are expected to grow at a relatively sluggish rate, with upward growth traction expected in the mid of the forecast period.


About Coherent Market Insights:


Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.


Contact Us:


Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Small Molecule Cancer Drugs Market to Reap Excessive Revenues by 2027

Cancer is a chronic condition that involves abnormal growth of cell. Interference due to genetic changes causes uncontrollable growth of cells and results into formation of a mass called tumor. The tumor is malignant type, it is capable to spread all over the body. Most of the cancer occur due to genetic mutation, induced due to environmental factors or lifestyle, or it can be hereditary also. It is classified into four categories on the basis of its origin – 1) Carcinoma (begins in skin or tissue) 2) Sarcoma (begins in connective tissues) 3) Lymphoma (begins in lymphatic system) 4) Leukemia (begins in blood).


Request For a Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/2754


Global Small Molecule Cancer Drugs Market Drivers


Approvals for small molecule cancer drugs by regulatory bodies to key players are expected to boost the global small molecule cancer drugs market growth. For instance, in May 2019, U.S. Food & Drug Administration (FDA) approved a drug, Piqray in combination with fluvestrant, which is manufactured by Novartis AG. It is the first ever drug that is specifically being used for the treatment of HR/HER2-, PIK3CA mutated advanced breast cancer.


Similarly, in April 2019, Janssen Pharmaceutical Company received U.S. FDA approval for Balversa (erdafitinib). It is indicated for the treatment of FGFR3 or FGFR2 mutated, locally advanced urothelial carcinoma. The type of study was multicenter, open-label, single-arm trial and comprised 87 participants diagnosed with locally advanced or metastatic urothelial carcinoma and had progressed on or after at least one prior chemotherapy.


Global Small Molecule Cancer Drugs Market Key Players


Some of the major players operating in the small molecule cancer drugs market include, Otsuka Pharmaceutical Co. Ltd, Eli Lilly and Co, Janssen Research and Development LLC, Novartis AG, Pfizer Inc., SANOFI AVENTIS US LLC, Baxter Healthcare Corp., Emcure Pharmaceuticals Ltd., AstraZeneca, Kyowa Kirin Inc., and HQ Specialty Pharma Corp


Global Small Molecule Cancer Drugs Market Taxonomy


The global small molecule cancer drugs market is segmented on the basis of drug class, route of administration, distribution channel, and regions. 


By Drug Class

  • Alkylating Agents

  • Plant Alkaloids

  • Antitumor Antibiotics

  • Antimetabolites

  • Topoisomerase Inhibitors

  • Others

By Route of Administration

  • Oral

  • Injectable

By Distribution Channel

  • Hospital pharmacies

  • Retail pharmacies

  • Online pharmacies


Global Small Molecule Cancer Drugs Market Regional Analysis


North America is expected to hold a dominant position in global small molecule cancer drugs market, owing to initiatives taken by other organizations related to cancer drugs. For instance, in June 2019, American Cancer Society partnered with Ovarian Cancer Research Alliance to fund research activities related to detection, treatment and prevention of ovarian cancer. Its goal is to raise funds for research activities, so as to support them for investigation of drugs for ovarian cancer. Hence, such initiatives may have a positive influence on the global small molecule cancer drugs market growth.


Global Small Molecule Cancer Drugs Market Restraints


Side-effects of drugs is expected to hamper the global small molecule cancer drugs market growth. The side-effects depend mainly upon the type of cancer and the overall health of the patient. It can cause muscle pain, headache, fatigue, mouth sores, nausea, vomiting, throat sores, diarrhea, and constipation. As these drugs effect healthy cells, in turn, affecting the process of regenerating new blood cells. Hence, this factor may obstruct the global Small Molecule Cancer Drugs Market growth.


About Coherent Market Insights:


Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.


Contact Us:


Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Sarcopenia Treatment Market at a Rapid Pace Until 2026

Sarcopenia means loss of skeletal muscle mass or loss of flesh by aging. Sarcopenia is associated with functional impairments in tasks such as standing up from a chair or lifting 10 pounds and physical disabilities such as not able to perform home chores and personal care. The loss of muscle tissue may progress more rapidly after the age of 60 or 70, however the exact rate of decline may vary, and a person may lose 3-8% of muscle mass per decade. Symptoms of Sarcopenia include decrease in muscle size, weakness, loss of endurance, trouble in climbing stairs and poor balance.


Request For a Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/2770


Sarcopenia Treatment Market Drivers


Increasing geriatric population is expected to boost growth of the sarcopenia treatment market growth. According to the World Health Organization, by 2050, the world’s population aged 60 years and above is expected reach 2 billion from 900 million in 2015. The conferences, meetings held by the foundations help to expand and share the knowledge and information about the sarcopenia treatment which will in turn drives the growth of sarcopenia treatment market. For instance, in April 2017, the U.S. Food and Drug Administration (FDA) held its public meeting on Patient Focused Drug Development (PFDD) for sarcopenia. The focus of the meeting was to obtain patient perspectives on symptoms and daily impacts of their condition.


Increasing investments in production of drugs and supplements are expected to boost growth of the sarcopenia treatment market. Furthermore, a growing number of pharmaceutical and food processing companies are focused on developing nutrition supplements for treatment of sarcopenia. For instance, in February 2016, Nestle announced that it has made a strategic investment for of USD 42.5 million in Pronutria Biosciences. The Nestlé’s cash will used by Pronutria Biosciences to develop a new compound called PN-107, which has the potential to tackle muscle loss caused by aging, prolonged bed rest. These factors are expected to drive growth of the sarcopenia treatment market.


Sarcopenia Treatment Market Key Players


Some of the major players operating in the sarcopenia treatment market include GlaxoSmithKline, Radius Health Inc., Five Prime Therapeutics, Inc., Abbott Laboratories, Pfizer Inc., Nestle S.A., Sanofi S.A., Bayer AG, and Novartis AG, Cadila Healthcare Ltd.


Sarcopenia Treatment Market Taxonomy


On the basis of treatment type, the global sarcopenia treatment market is segmented into:

  • Protein Supplement

  • Vitamin D and Calcium Supplement

  • Vitamin B12 Supplement

On the basis of distribution channel, the global sarcopenia treatment market is segmented into:

  • Hospital pharmacies

  • Retail pharmacies

  • Online pharmacies

  • Hypermarket and Supermarket


Sarcopenia Treatment Market Regional Analysis


North America is expected to hold a dominant position in the sarcopenia treatment market, owing to presence of developed healthcare facilities and infrastructure in countries such as the U.S, and Canada. Moreover, the demand for sarcopenia treatment has increased in the region due to high focus on healthcare by the government, technological advancements are likely to fuel growth of the sarcopenia treatment market during the forecast period.


Europe is expected to be the second largest Sarcopenia Treatment Market over the forecast period. For instance, in February 2019, Biophytis SA, a Paris (France) based company focused on development of novel therapeutics for age-related diseases, announced three oral and poster presentations at the 2019 International Conference on Frailty and Sarcopenia Research (ICFSR). In this conference, the company presented the details of its lead clinical drug candidate, Sarconeos (BIO 101), that included its history and unique mechanism that targets the MAS receptor for preservation of muscle function in muscle wasting disorder. In addition, the company also presented the clinical trial design of its ongoing SARA Phase 2 study of Sarconeos to treat sarcopenia.


About Coherent Market Insights:


Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.


Contact Us:


Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Hemoglobinopathy Treatment Market is Anticipated to Show Growth by 2027

Hemoglobinopathy includes a range of disorders, which occur due to altered structure of hemoglobin. Hemoglobin is present in the red blood cells that transports oxygen from the lung to the body. Hemoglobinopathy disorder are inherited and are passed on from one generation to another. It is further classified into two categories – 1. Thalassemia Syndrome 2. Structural Hemoglobin Variants. Thalassemia syndrome includes disorder related to synthesis defect. The synthesis defect of alpha globin gives rise to alpha thalassemia and defect in beta globin give rise to beta thalassemia. The structural hemoglobin variants occur due to alteration of alpha and beta chains that causes defect in structure.


Request For a Sample Copy of This Business Report @

https://www.coherentmarketinsights.com/insight/request-sample/2801


Global Hemoglobinopathy Treatment Market Drivers


Increasing research and development activities are expected to support global hemoglobinopathy treatment market growth over the forecast period. For instance, in September 2018, AstraZeneca initiated its clinical trial for Ticagrelor. It is being studied for the treatment of sickle cell disease. The drug is being studied for the evaluation of its safety and efficacy. Currently, it is in the third phase of clinical trial.


Furthermore, in January 2019, Celgene Corporation and Acceleron Pharma Inc. started their clinical trial for luspatercept. It is being studied for the treatment of adult patients with beta-thalassemia. The drug is being tested for its safety, efficacy, and pharmacokinetics. In June 2019, the U.S. Food & Drug Administration (FDA) accepted biologics license application (BLA) of luspatercept. Hence, such developments are expected to drive the global hemoglobinopathy treatment market growth.


Furthermore, key players are indulged in obtaining approvals from regulatory bodies for their products, which is expected to impel the global hemoglobinopathy treatment market growth. For instance, June 2019, Bluebird Bio Inc. received the European Medicines Agency (EMA) approval for its product, Zynteglo. It is a gene therapy, which contains autologous CD34+ cells encoding βA-T87Q-globin gene. It is indicated for patients aged 12 years and above with transfusion-dependent β-thalassemia who do not have the β0/β0 genotype. Hence, such approvals are expected to impact positively on the global hemoglobinopathy treatment market growth.


Global Hemoglobinopathy Treatment Market Key Players


Some of the major players operating in the global hemoglobinopathy treatment market include, Novartis AG, AstraZeneca, Bluebird Bio Inc., Bristol-Myers Squibb, Emmaus Medical, Inc., Acceleron Pharma, Inc., HemaQuest Pharmaceuticals Inc., Eli Lilly and Company, Celgene Corporation, and Acceleron Pharma, Inc.


Global Hemoglobinopathy Treatment Market Taxonomy


By Drug

  • Hydroxyurea

  • Glutamine

  • Zynteglo (autologous CD34+ cells encoding βA-T87Q-globin gene)

  • Luspatercept

  • Others

By Disease Type

  • Sickle Cell Diseases

  • Thalassemia

    • Alpha thalassemia

    • Beta Thalassemia

  • Others


Global Hemoglobinopathy Treatment Market Regional Analysis


North America is expected to hold dominant position in global hemoglobinopathy treatment market. Factors such as increase in prevalence of hemoglobinopathy disorders are expected to drive the global hemoglobinopathy treatment market growth. According to the data published by National Centre for Biotechnology Information (NCBI), in 2019, around 300,000 infants are born with sickle cell anemia annually and the population of sickle cell anemia is 100,000 in the U.S. Hence, higher prevalence of sickle cell anemia may increase the demand for treatment, thereby expected to support the global hemoglobinopathy treatment market growth.


Global Hemoglobinopathy Treatment Market Restraints


Rejection of approvals related to hemoglobinopathy treatment by the regulatory bodies is expected to hamper the global hemoglobinopathy treatment market growth. For instance, in May 2019, European Medical Agency (EMA) rejected an approval of a drug, Xyndari.  Xyandri was manufactured by Emmaus Medical, Inc. It was being developed for the treatment of patients with sickle cell disease. Hence, this factor may have a negative impact on the global Hemoglobinopathy Treatment Market growth.


About Coherent Market Insights:


Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.


Contact Us:


Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

PTA Balloon Catheter Market Provides An In-Depth Insight Of Sales And Trends Forecast To 2026

A catheter is a tubular, flexible instrument, passed through body channels for withdrawals of fluid (or introduction of fluids) from body cavity. PTA balloon catheter is an innovative medical device, which is inserted in the femoral artery in the leg or sometimes into the radial artery in the arm for the treatment of constricted blood vessels. The PTA means “percutaneous transluminal angioplasty” (percutaneous means through the skin). As the balloon inflates, the cage causes the balloon to form a series of segmented pillows and grooves along the entire lesion. The pillows apply force to create small dissections that are necessary for effective dilatation. The grooves relieve the stress and stop dissections from propagating. The PTA balloon catheters is used in for the treatment of peripheral vascular lesions.


Request For a Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/2815


Market Dynamics


Increasing prevalence of urological and cardiovascular diseases, geographical expansion of PTA balloons catheter manufacturers in North America, and increasing investment in research and development by manufacturers are some of the major factors that are expected to drive the market growth. Furthermore, increasing production of PTA balloon catheter is expected to driving growth of global PTA balloon catheter market. For instance, in April 2015, BrosMed announced CE mark and launched its Minerva percutaneous transluminal angioplasty (PTA) dilation catheter for the treatment of patients with peripheral arterial disease.


Increasing prevalence of urological and cardiovascular diseases is expected to propel the PTA balloon catheter market growth


Increasing prevalence of urological and cardiovascular diseases is expected to increase demand for PTA balloon catheters, which in turn is expected to fuel the PTA balloon catheter market growth over the forecast period. The urological diseases include, urinary tract infections, kidney stones, and prostate problems. According to, the American Cancer Society around 174,650 new cases and around 31,620 deaths occurs due to prostate cancer the U.S. in 2019. According to National Institute of Diabetes and Digestive and Kidney Diseases, in 2017, around 11% of men and 6% of women in the U.S. suffered from kidney stone.


Furthermore, according to the World Health Organization, cardiovascular diseases account for most of the non-communicable disease deaths. An estimated 17.9 million deaths were registered from cardiovascular diseases in 2016, representing 31% of the global deaths. Of these deaths, 85% were due to heart attack and stroke. Therefore, increasing prevalence of non-communicable diseases is expected to increase demand for catheters, which in turn is expected to drive growth of the PTA Balloon Catheter Market over the forecast period.


Key Players


Major players operating in the global PTA balloon catheter market include, Medtronic, Terumo, Cardinal Health, Boston Scientific, AndraTec, Cook Medical, Biotronik, Abbott, Creagh Medical, TriReme Medical, and Natec Medical.


Detailed Segmentation:

  • Global PTA balloon catheter Market, By Material Type:

    • Polyurethane

    • Nylon

    • Others

  • Global PTA balloon catheter Market, By Application:

    • Coronary Artery Disease

    • Peripheral Vascular Disease

  • Global PTA balloon catheter Market, By End User:

    • Hospitals and Clinics

    • Ambulatory Surgical Centers

    • Others


Increasing Launch of New Products Is Expected To Boost the PTA Balloon Catheter Market Growth in North America


Major PTA balloon catheter manufacturers are focused on launching new products in North America to enhance their market share. For instance, in February 2016, Nipro North America, a division of Nipro Medical Corporation, announced the launch of Cronus HP high pressure, 0.035” over the wire (OTW) percutaneous transluminal angioplasty (PTA) balloon catheter. Cronus HP is indicated for percutaneous transluminal angioplasty in the femoral, popliteal, iliac, and renal arteries and for the treatment of obstructive lesions in native or synthetic arteriovenous dialysis fistulae.


Moreover, in February 2017, QT Vascular Ltd. signed an exclusive, worldwide distribution agreement with Medtronic to distribute the Chocolate PTA balloon catheter. It is currently available in the U.S. and Europe.


About Coherent Market Insights:


Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.


Contact Us:


Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Single Use Disposable Patient Positioning Products Market Poised to Take Off by 2026

Single use disposable patient positioning products are extensively used in hospitals, specialty care, and homecare setting. Products such as single use knee pads, arm cradles, and heel protectors are in demand among patients, as they can be used in home care settings. Single use disposable patient positioning products are preferred by hospitals, as these products are cost-effective, time saving, and prevent cross-contamination. The global single use disposable patient positioning market is expected to grow in the near future, owing to increasing number of surgeries and chronic disorders.


Request For a Sample Copy of This Business Report @ 
https://www.coherentmarketinsights.com/insight/request-sample/2833


Market Dynamics


The increasing prevalence of musculoskeletal disorders is expected to drive growth of the single use disposable patient positioning market in the forecast period. For instance, according to a report of State of Musculoskeletal Health 2018, around 17.8 million people in the U.K. had a musculoskeletal condition, which was around 28.9% of U.K.’s total population in 2017.


Increasing prevalence of musculoskeletal disorders and increasing number of orthopedic surgeries is expected to drive growth of the Global Single Use Disposable Patient Positioning Products Market.


Increasing prevalence of musculoskeletal disorders is expected to lead to high demand for single use disposable patient positioning products over the forecast period. For instance, the American Academy of Orthopedic Surgeons’ (AAOS) report of March 2016 estimated that around 126.6 million people in the U.S. (one in two adults) are affected by a musculoskeletal condition.


Single use disposable patient positioning market is expected to witness further growth owing to an increasing number of orthopedic surgeries. For instance, according to the Major Orthopedic Surgery report of 2011, 5.3 million orthopedic surgeries were carried out in seven major countries (U.S., Japan, France, Germany, Italy, Spain, and U.K.) in 2010 and the number is projected to increase to around 6.6 million in 2020 due to the aging population.


Global Single Use Disposable Patient Positioning Products Market - Competitive Landscape


Key players operating in the global single use disposable patient positioning products market include Stryker Corporation, Steris Plc., Smith & Nephew Plc., Hill-Rom Holdings, Inc., Prime Medical, LLC, Getinge AB, Xodus Medical, Inc., Soule Medical, Infinitus Medical, D.A. Surgical, Cardinal Health, Inc., Innovative Medical Products, Inc., and Mizuho Osi.


Detailed Segmentation:

  • Global Single Use Disposable Patient Positioning Market, By Product Type:

    • Table Pads

      • Trendelenburg Positioners

      • Others

    • Headrests/Holders

    • Heel/Elbow Protectors

    • Arm Cradles

    • Securing Devices (Safety Belts, Tapes, Vacuum Beanbags)

    • Cushions

  • Global Single Use Disposable Patient Positioning Market, By Application:

    • Surgery

    • Disease Diagnosis

  • Global Single Use Disposable Patient Positioning Market, By End User:

    • Hospitals

    • Specialty Centers

    • Homecare Settings


Global Single Use Disposable Patient Positioning Products Market - Regional Insights


On the basis of region, the global single use disposable patient positioning products market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global single use disposable patient positioning products market during the forecast period, owing to increasing strategic acquisitions by key players. For instance, in July 2017, Cardinal Health, Inc. announced the acquisition of Medtronic's Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency business for US$ 6.1 billion. The acquisition further expanded the product portfolio of Cardinal Health’s medical segment.


Asia Pacific is expected to foresee a rapid growth in the global Single Use Disposable Patient Positioning Products Market in the forecast period, owing to increasing prevalence of sports injuries. Products such as knee pads, foot positioners, elbow and arm positioners, shoulder positioners, and others are extensively used to treat sports-related injuries. For instance, according to the 2014 report from the Australian Institute of Health and Welfare (AIHW), there were 36,000 sports injury hospitalizations in 2012-2013, which included people aged 15 and above.


About Coherent Market Insights:


Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.


Contact Us:


Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Outsourced Drug Discovery Market To Be At Forefront By 2026

Outsourced drug discovery is a contract-based process, which is conducted by the contract research organizations (CRO) and contract manufacturing organization (CMO). Contract research organization provides support to pharmaceutical, biotechnology, and medical device industries for drug discovery and development. CRO facilitates the various services such as biopharmaceutical development, biologic assay development, preclinical research, clinical trials, and pharmacovigilance, for drug discovery and development.


Request For a Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/2847


Market Dynamics


New strategies adopted by key players related to outsourcing drug discovery is expected to drive growth of global outsourced drug discovery market. For instance, in June 2019, GlaxoSmithKline (GSK), a British drug manufacturing company collaborated with the University of California to establish a state-of-the-art laboratory for CRISPR technologies, the Laboratory for Genomics Research (LGR), in San Francisco. The new laboratory will investigate how gene mutations cause diseases, and also develop new technologies using CRISPR to rapidly accelerate the discovery of new medicines.


Furthermore, extension of partnership activities is expected to propel global outsourced drug discovery market growth. For instance, in March 2017, Charles River Laboratories (CRL) extended its partnership with Chiesi Farmaceutici. Under this partnership, Charles River Laboratories (CRL) extended its longstanding, strategic, integrated drug discovery program (Respiratory Program). The respiratory program is related to the preclinical drug development for treatment of respiratory diseases and rare diseases.


Increasing number of drug discovery companies is expected to drive growth of the global outsourced drug discovery market


Increasing number of new drug discovery companies is expected to drive the global outsourced drug discovery market growth. For instance, in November 2018, Schrodinger, LLC collaborated with Wuxi AppTec and launched new drug discovery company, Faxian Therapeutics (Headquarter– New York, U.S.). Faxian Therapeutics will utilize the Schrodinger, LLC’s computational platform and WuXi’s drug design and synthesis services to improve health care needs.


Global Outsourced Drug Discovery Market - Competitive Landscape


Key players operating in the global outsourced drug discovery market are Aurigene Accelerating Discovery, Bioduro LLC, Charles River Laboratories (CRL), Chempartner, TCG Lifesciences, Evotec AG, Syngene International Ltd., Jubilant Biosys Ltd, Pharmaron Inc., Shanghai Medicilon, and Sundia Meditech Co. Ltd.


Detailed Segmentation:

  • Global Outsourced Drug Discovery  Market, By Drug Type:

    • Small Molecule Drugs

    • Large Molecule Drugs

  • Global Outsourced Drug Discovery market, By Services:

    • Preclinical Development

    • Target Validation and Functional Informatics

    • Target Identification and Screening

    • Lead Identification and Candidate Optimization

    • Others

  • Global Outsourced Drug Discovery Market, By Application

    • Oncology

    • Ophthalmology

    • Hematology

    • Immunomodulation

    • Anti-Infective Drugs

    • Dermatology

    • Pulmonology

    • Cardiology

    • Others

  • Global Outsourced Drug Discovery market, By End User

    • Pharmaceutical and Biotechnological Companies

    • Contract Research Organization

    • Contract Manufacturing Organization


Global Outsourced Drug Discovery Market- Regional Analysis


North America outsourced drug discovery market is expected to account for the largest market share, owing to business expansion in this region. For instance, in January 2019, Lambda Therapeutic Research (Headquarter-India) acquired Novum Pharmaceutical Research Services, a U.S. CRO. With this acquisition, Lambda Therapeutic Research entered into the U.S. market.


Moreover, Europe is also projected to witness significant growth in the global outsourced drug discovery market, owing to increasing merger and acquisition activities by key players in the region. For instance, in February 2019, Optimapharm, a clinical research organization (CRO) in Europe acquired Denothex, a CRO, for strengthening its presence in the European market particularly in France, Spain, Switzerland, and Italy. Denothex conducts all clinical trials in oncology across Europe and Israel.


Asia Pacific is also projected to witness significant growth in the global Outsourced Drug Discovery Market, owing to increasing launches of IT infrastructure investment programs (Trial Management and Monitoring Cloud Service Implementation Program) for development of clinical trials. For instance, in December 2018, Novotech, a CRO, launched new Oracle Trial Management and Monitoring Cloud Service Implementation Program (TMMCS) in Asia-Pacific.TMMCS helps to maintain centralized trial management database and clinical research associate productivity. TMMCS provides various benefits including better trial results, improved investigator relationship, and lower trial costs.


About Coherent Market Insights:


Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.


Contact Us:


Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Wearable Patch Market: Technological Innovations 2026

Wearable patches are known as smart patches or electronic skin. Wearable patches are thin, small, and flexible in nature, and are used for disease monitoring, drug delivery, and diagnosis. Also, wearable patch help to maintain health and well-being in elderly patients suffering from chronic conditions such as diabetes, lung disease, etc. Presently, the market of wearable technologies is increasing due to research and development activities carried out by companies. Wearable patches can be used in several ways, such as patches which can be worn on the body or stuck to the skin, or patches such as scopolamine patches and transdermal patches which can be directly attached to the affected organ for disease monitoring. A nicotine patch is a transdermal patch which releases nicotine into the body, and is used in nicotine replacement therapy (NRT).


Request For a Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/2891


Wearable Patch Market- Drivers


Increasing incidence of chronic diseases such as diabetes, cancer, and heart disease is one of the key factors driving the market growth. Wearable patches are non-invasive devises use for a longer period of time. Advances are made in user comfort, sensor accuracy and demonstration of wearable patch and its uses in both clinical and non-clinical area. Increase in healthcare expenditure has led to higher demand for wearable products, which is projected to facilitate growth of the wearable patch market over the forecast period.


Wearable Patch Market – Market Taxonomy

  • On the basis of product type, the global wearable patch market is segmented into:

    • Blood Glucose Patch

    • Temperature Patch

    • Blood Pressure Patch

    • Heart Rate Patch

    • ECG Patch

    • Blood Oxygen Patch

  • On the basis of technology, the global wearable patch market is segmented into:

    • Connected

    • Regular

  • On the basis of application, the global wearable patch market is segmented into :

    • Clinical

    • Non-clinical

  • On the basis of end user, the global wearable patch market is segmented into :

    • Healthcare

    • Fitness

    • Sports


Wearable Patch Market – Competitive Land Scape


Key players operating in the global wearable patch market include Abbott Laboratories, Kenzen, Gentag, Proteus Digital Health, Insluet, Nemaura Medical, Proteus Digital Health, Cequr, Chrona Therapeutics, Dexcom, Feeligreen, Fitlinxx, and G-Tech Medical. Some other major companies are Medtronic, Loreal, Irhythm Technology, Leaf Healthcare, Delta Electronics, Zansors, X2 biosystems, and Valendo.


Wearable Patch Market - Regional Insights


In 2017, North America accounted for the highest growth in the wearable patch market owing to product launches and technological advancements in the region. In Jan 2019, L’Oreal launched the first wearable patch in U.S containing a microfluidic sensor which is useful for measuring the skin PH levels. As per the Business Standard press release, in May 2019, researchers from the University Of California developed a wearable temperature patch that cools or warms the wearer’s skin to a suitable temperature. According to the researchers, it can also save energy on heating and air conditioning.


The Europe wearable patch market is highly competitive due to presence of key players in the market such as Samsung, Microsoft, Google Inc. Moreover, increasing focus on product developments by key players is contributing to the growth and development of the wearable patch market in Europe.


Asia Pacific is also expected to exhibit positive growth in the Wearable Patch Market in the near future owing to increasing geriatric population in the region. As per the United Nations Population Fund, Asia Pacific report 2018, by 2050 one out of four people will be over 60 years of age, and aging population rate is growing at a rapid pace since 2010 and expected to reach around 1.3 billion people by 2050. Increasing government investment in technological advancement and rising healthcare expenditure is expected to propel growth of the wearable patch market. According to the Organization of Economic Co-operation and Development, Health Statistics report 2018, the healthcare spending rate in Asia Pacific region from 2010 – 2015 was 5.3% per year.


About Coherent Market Insights:


Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.


Contact Us:


Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com